Nurexone signs consulting agreement, closes financing

Executive Summary

• Nurexone Biologic Inc. closed a non-brokered private placement of 1,295,222 units for gross proceeds of approximately $880,751, intended for general working capital.
• The company appointed Dr. Lars Barfacker, a former Bayer scientist, as a consultant to support European scientific and strategic initiatives.
• Nurexone was named a finalist in the healthcare category of the 2026 BOLD Awards, with CEO Dr. Lior Shaltiel expected to attend the ceremony in Barcelona.

Key Details

• Financing Structure: Non-brokered private placement closed subject to TSX Venture Exchange approval.
• Units Sold: 1,295,222 units.
• Price: 68 cents per unit.
• Gross Proceeds: Approximately $880,750.96.
• Use of Proceeds: General working capital purposes.
• Insider Participation: No insiders participated in the offering.
• Finder’s Fees: No finders' fees were paid.
• Warrant Terms: Each unit includes one common share and one common share purchase warrant.
• Warrant Exercise Price: 85 cents per common share.
• Warrant Expiry: 36 months from the closing date.
• Acceleration Clause: If the daily volume weighted average trading price exceeds $1.70 for 20 consecutive trading days, the company may accelerate the warrant expiry to 30 days following written notice.
• Regulatory Holds: Securities are subject to a statutory hold period of four months and one day from the closing date.
• Consulting Agreement: Signed with Dr. Lars Barfacker, former principal research scientist at Bayer AG, with over two decades of experience in drug discovery (including Finerenone/Kerendia).
• Award Recognition: Named a finalist in the healthcare category of the 2026 BOLD Awards; ceremony scheduled for March 27, 2026, in Barcelona, Spain.

Notable Quotes

• "Lars brings many years of experience in the exosome field and a deep understanding of extracellular vesicle biology and its potential therapeutic applications, including his experience at Bayer. His perspective will be valuable as Nurexone continues advancing its regenerative medicine platform globally, particularly in Europe." — Dr. Lior Shaltiel, CEO
• "This financing strengthens our preclinical programs and advances the company along its milestone-based road map." — Eran Ovadya, CFO